Capital Medical Univ. HDAC6 compound 23a

Capital Medical Univ. HDAC6 compound 23a: sourced facts only. name: "Mechanistically, 23a exerted its antitumor effects through simultaneous targeting of HDAC6, DNA, and the release of high levels of nitric oxide (NO)." [PMID:40972425]; target: "Mechanistically, 23a exerted its antitumor effects through simultaneous targeting of HDAC6, DNA, and the release of high levels of nitric oxide (NO)." [PMID:40972425]; developer: "Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China." [PMID:40972425]; stage: "In a Lewis lung carcinoma (LLC) metastatic mouse model, 23a significantly inhibited pulmonary metastasis formation." [PMID:40972425]